The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 26 February 2026•Updated 26 February 2026•

1 min read

United Therapeutics Beats Q4 Estimates as Analysts Raise Price Targets on Strong Outlook

Key Facts

1United Therapeutics' revenues grew by over 10% in Q4 and FY2025.

3 months ago

Version History

Version 13 months ago

What changed: Updated to reflect the confirmed earnings beat and analysts raising their future price targets and forecasts based on recent performance.

United Therapeutics Corporation (UTHR) confirmed that its fourth-quarter earnings surpassed Wall Street expectations, with revenues climbing by more than 10%. The company's net income per share saw an impressive increase of approximately 14%, fueling a significant stock rally of over 75% as investor confidence surged. Following this strong performance, analysts have raised their future forecasts and price targets for the stock, reflecting significant optimism regarding the company's financial trajectory. A primary driver of this success remains the Tyvaso franchise, which continues to dominate the Pulmonary Arterial Hypertension (PAH) market. Looking ahead, the company is positioned for further growth with high-impact clinical catalysts, including Phase 3 data for ralinepag and results from the TETON-1/2 trials. This combination of superior earnings and a promising late-stage clinical pipeline reinforces the company's leadership position in the biotechnology sector.